AGIO

In the past six months, Agios Pharmaceuticals' stock price has been impacted by several key events. The stock declined by 29% over the three months leading up to October 6, 2026, largely due to setbacks with tebapivat, an investigational next-generation pyruvate kinase activator. In May 2026, Agios halted the development of tebapivat in lower-risk myelodysplastic syndromes (LR-MDS) after a Phase IIb study did not meet the predefined threshold for further development. This was followed by another setback in July 2026, when the company discontinued tebapivat's development in sickle cell disease (SCD), as the Phase II study data did not demonstrate sufficient differentiation from existing PK activators to justify further development. These decisions have narrowed Agios's pipeline and raised concerns about diversifying growth beyond its mitapivat franchise. Conversely, strong growth in mitapivat sales in the second quarter of 2026 provided a positive counterpoint, with net product revenue of $44.7 million from mitapivat (PYRUKYND/AQVESME), a significant increase from $12.5 million in the same period in 2025, driven by the U.S. AQVESME thalassemia launch and growing ex-U.S. PYRUKYND sales. The U.S. commercial launch of AQVESME in thalassemia began in late January 2026, and the European Commission granted marketing authorization for PYRUKYND in adults for anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia in May 2026. Additionally, the U.S. FDA granted Priority Review to Agios's supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, with a PDUFA goal date of November 1, 2026, which is seen as a material de-risking event for a potential launch.